Scott Biller Sells 3,000 Shares of Agios Pharmaceuticals Inc (AGIO) Stock

Share on StockTwits

Agios Pharmaceuticals Inc (NASDAQ:AGIO) insider Scott Biller sold 3,000 shares of Agios Pharmaceuticals stock in a transaction dated Monday, November 5th. The stock was sold at an average price of $69.69, for a total value of $209,070.00. Following the completion of the transaction, the insider now owns 53,932 shares of the company’s stock, valued at approximately $3,758,521.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Scott Biller also recently made the following trade(s):

  • On Friday, October 5th, Scott Biller sold 3,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $69.79, for a total value of $209,370.00.
  • On Wednesday, September 5th, Scott Biller sold 3,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $83.07, for a total value of $249,210.00.

Shares of NASDAQ:AGIO traded up $1.44 during trading hours on Wednesday, hitting $72.78. 520,500 shares of the company’s stock traded hands, compared to its average volume of 461,773. Agios Pharmaceuticals Inc has a 1 year low of $51.62 and a 1 year high of $99.82. The firm has a market capitalization of $4.09 billion, a PE ratio of -10.78 and a beta of 2.04.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, November 1st. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.62) by ($0.01). Agios Pharmaceuticals had a negative net margin of 461.78% and a negative return on equity of 48.51%. The business had revenue of $15.20 million for the quarter, compared to analysts’ expectations of $22.72 million. During the same quarter last year, the firm earned ($1.59) EPS. The firm’s quarterly revenue was up 33.8% on a year-over-year basis. Analysts expect that Agios Pharmaceuticals Inc will post -6.21 earnings per share for the current fiscal year.

Several institutional investors have recently bought and sold shares of the company. United Services Automobile Association raised its stake in shares of Agios Pharmaceuticals by 9.6% during the second quarter. United Services Automobile Association now owns 8,050 shares of the biopharmaceutical company’s stock valued at $678,000 after acquiring an additional 708 shares in the last quarter. Xact Kapitalforvaltning AB raised its stake in shares of Agios Pharmaceuticals by 13.0% during the second quarter. Xact Kapitalforvaltning AB now owns 7,823 shares of the biopharmaceutical company’s stock valued at $659,000 after acquiring an additional 900 shares in the last quarter. Amalgamated Bank raised its stake in shares of Agios Pharmaceuticals by 11.4% during the second quarter. Amalgamated Bank now owns 11,667 shares of the biopharmaceutical company’s stock valued at $983,000 after acquiring an additional 1,194 shares in the last quarter. State of Alaska Department of Revenue raised its stake in shares of Agios Pharmaceuticals by 32.7% during the second quarter. State of Alaska Department of Revenue now owns 5,960 shares of the biopharmaceutical company’s stock valued at $501,000 after acquiring an additional 1,470 shares in the last quarter. Finally, Principal Financial Group Inc. raised its stake in shares of Agios Pharmaceuticals by 11.5% during the first quarter. Principal Financial Group Inc. now owns 14,895 shares of the biopharmaceutical company’s stock valued at $1,218,000 after acquiring an additional 1,533 shares in the last quarter. 94.38% of the stock is owned by hedge funds and other institutional investors.

AGIO has been the subject of several recent research reports. Cann reiterated a “hold” rating on shares of Agios Pharmaceuticals in a research report on Friday, July 20th. SunTrust Banks restated a “buy” rating and set a $123.00 target price on shares of Agios Pharmaceuticals in a research report on Monday, July 23rd. Piper Jaffray Companies set a $125.00 target price on Agios Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 2nd. Canaccord Genuity restated a “buy” rating on shares of Agios Pharmaceuticals in a research report on Thursday, August 2nd. Finally, Needham & Company LLC restated a “buy” rating on shares of Agios Pharmaceuticals in a research report on Thursday, August 2nd. Five equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $96.27.

ILLEGAL ACTIVITY NOTICE: This article was originally published by Week Herald and is the property of of Week Herald. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://weekherald.com/2018/11/07/scott-biller-sells-3000-shares-of-agios-pharmaceuticals-inc-agio-stock.html.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

Featured Story: Index Funds

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply